Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Historical Holders from Q2 2019 to Q1 2025

Symbol
QNCX on Nasdaq
CUSIP
22053A107
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
43.2M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
5.11M
Holdings value
$9.55M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
36
Number of buys
17
Number of sells
-12
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Genextra S.p.A. 6.49% $3.73M 2.81M Genextra S.p.A. Oct 18, 2024
Sofinnova Partners SAS 5.4% $3.19M 2.4M Sofinnova Capital VIII Dec 31, 2024

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 64.7K $86.1K +$70.9K $1.33 3
2024 Q4 5.11M $9.55M +$494K $1.87 36
2024 Q3 5.19M $4.04M -$768K $0.78 32
2024 Q2 6.24M $4.67M -$801K $0.75 40
2024 Q1 7.26M $7.7M -$189K $1.06 43
2023 Q4 7.43M $7.8M -$53.7K $1.05 39
2023 Q3 7.48M $8.38M -$2.28M $1.12 38
2023 Q2 8.95M $13.5M +$1.95M $1.51 36
2023 Q1 7.62M $11.9M +$3.8M $1.56 38
2022 Q4 5.36M $3.41M -$3.3M $0.64 44
2022 Q3 9.09M $12.1M -$3.52M $1.33 50
2022 Q2 11M $24.5M -$25.4M $2.22 57
2022 Q1 11.4M $70.8M -$28M $6.19 79
2021 Q4 16.6M $210M -$233M $12.62 90
2021 Q3 19.2M $1.76B +$81.3M $91.66 130
2021 Q2 18.5M $982M -$6.01M $53.00 104
2021 Q1 18.7M $673M +$37.6M $36.03 89
2020 Q4 17.7M $491M +$26.9M $27.78 84
2020 Q3 16.5M $827M +$55.4M $50.00 83
2020 Q2 15.4M $715M +$185M $46.30 81
2020 Q1 11.5M $523M +$39.6M $45.61 65
2019 Q4 10.6M $594M +$91.8M $56.14 50
2019 Q3 5.84M $145M +$81.5M $24.93 40
2019 Q2 2.42M $103M +$103M $42.51 36